A phase IB clinical trial of 15  Gy HDR brachytherapy followed by hypofractionated/SBRT in the management of intermediate-risk prostate cancer

High dose-rate (HDR) brachytherapy is commonly administered as a boost to external beam radiation therapy (EBRT). Our purpose was to compare toxicity with increasingly hypofractionated EBRT in combination with a single 15  Gy HDR boost for men with intermediate-risk prostate cancer.

Source: Brachytherapy - March 22, 2020 Category: Cancer & Oncology Authors: Robert B. Den, Jacob Greenspan, Laura A. Doyle, Amy S. Harrison, Cheng Peng, Noelle L. Williams, Costas D. Lallas, Edouard J. Trabulsi, Leonard G. Gomella, Mark D. Hurwitz, Benjamin Leiby, Adam P. Dicker Source Type: research